Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Bristol-Myers Squibb Co (BMY)  
$44.71 0.35 (0.78%) as of 4:30 Tue 5/14


Download
   
Exchange: New York Stock Exchange
Security Type: Common
Shares Out: 2,250,000,000
Market Cap: 100.60(B)
Last Volume: 14,535,649 Avg Vol: 11,963,293
52 Week Range: $43.67 - $69.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Major

Member Indexes:
    S&P COMPOSITE 1500     NYSE COMPOSITE
    S&P 100     S&P 500

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 11.3
Insider 3/6 Months : 11.9
Guru Rank Number :  97
Guru Rank Value     : 8.6
Guru Occurances    : 3

 

            6 Months   1 Year   2 Year  
 
Company Profile   Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 13,571 13,571 13,571
Total Buy Value $0 $672,994 $672,994 $672,994
Total People Bought 0 2 2 2
Total Buy Transactions 0 3 3 3
Total Shares Sold 0 0 18,718 681,397
Total Sell Value $0 $0 $1,146,397 $49,727,684
Total People Sold 0 0 2 6
Total Sell Transactions 0 0 2 12
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 2225
  Page 15 of 89  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bancroft Charles A EVP, Head of Integration   •       –      –    2020-03-10 4 A $0.00 $0 D/D 7,075 158,045     -
   Bancroft Charles A EVP, Head of Integration   •       –      –    2020-03-10 4 OE $0.00 $0 D/D 71,868 153,637     -
   Bancroft Charles A EVP, Head of Integration   •       –      –    2020-03-10 4 D $0.00 $0 D/D (397) 106,408     -
   Bancroft Charles A EVP, Head of Integration   •       –      –    2020-03-10 4 GA $0.00 $0 I/I 300,000 300,000     -
   Bancroft Charles A EVP, Head of Integration   •       –      –    2020-03-10 4 GD $0.00 $0 D/D 300,000 92,309     -
   Eid Joseph SVP,Head Glob. Medical Affairs   •       –      –    2020-03-10 4 D $57.93 $36,786 D/D (635) 6,445     -
   Eid Joseph SVP,Head Glob. Medical Affairs   •       –      –    2020-03-10 4 A $0.00 $0 D/D 212 6,864     -
   Eid Joseph SVP,Head Glob. Medical Affairs   •       –      –    2020-03-10 4 OE $0.00 $0 D/D 1,571 6,652     -
   Eid Joseph SVP,Head Glob. Medical Affairs   •       –      –    2020-03-10 4 D $0.00 $0 D/D (30) 5,922     -
   Boerner Christopher S. EVP, Chief Commercial Officer   •       –      –    2020-03-10 4 D $57.43 $701,756 D/D (12,167) 21,033     -
   Boerner Christopher S. EVP, Chief Commercial Officer   •       –      –    2020-03-10 4 A $0.00 $0 D/D 2,497 27,190     -
   Boerner Christopher S. EVP, Chief Commercial Officer   •       –      –    2020-03-10 4 OE $0.00 $0 D/D 21,426 26,091     -
   Boerner Christopher S. EVP, Chief Commercial Officer   •       –      –    2020-03-10 4 D $0.00 $0 D/D (109) 12,811     -
   Von Autenried Paul EVP, Chief Information Officer   •       –      –    2020-03-10 4 D $57.93 $622,052 D/D (10,738) 146,701     -
   Von Autenried Paul EVP, Chief Information Officer   •       –      –    2020-03-10 4 A $0.00 $0 D/D 2,030 153,636     -
   Von Autenried Paul EVP, Chief Information Officer   •       –      –    2020-03-10 4 OE $0.00 $0 D/D 20,806 152,400     -
   Von Autenried Paul EVP, Chief Information Officer   •       –      –    2020-03-10 4 D $0.00 $0 D/D (124) 139,268     -
   Elicker John E EVP, Investor Relations   •       –      –    2020-03-04 4 S $61.01 $964,263 D/D (15,805) 58,666 6%     
   Vessey Rupert Pres., Research & Early Dev.   •       –      –    2020-03-02 4 S $60.59 $5,108,222 D/D (84,308) 48,343 5%     
   Vessey Rupert Pres., Research & Early Dev.   •       –      –    2020-03-02 4 OE $38.41 $4,831,452 D/D 93,468 132,651     -
   Elkins David V EVP, Chief Financial Officer   •       –      –    2020-03-01 4 D $59.06 $618,358 D/D (10,470) 34,296     -
   Elkins David V EVP, Chief Financial Officer   •       –      –    2020-03-01 4 OE $0.00 $0 D/D 24,579 44,766     -
   Vessey Rupert Pres., Research & Early Dev.   •       –      –    2020-03-01 4 D $59.06 $526,992 D/D (8,923) 39,183     -
   Vessey Rupert Pres., Research & Early Dev.   •       –      –    2020-03-01 4 OE $0.00 $0 D/D 23,349 48,106     -
   Ahmed Nadim President, Hematology   •       –      –    2020-03-01 4 D $59.06 $500,415 D/D (8,473) 24,555     -
  2225 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 15 of 89
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us